Edition:
United States

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

306.48USD
12:56pm EDT
Change (% chg)

$-4.07 (-1.31%)
Prev Close
$310.55
Open
$310.17
Day's High
$312.09
Day's Low
$306.48
Volume
164,774
Avg. Vol
648,512
52-wk High
$333.24
52-wk Low
$223.03

BIIB.OQ

Chart for BIIB.OQ

About

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA,... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $68,047.95
Shares Outstanding(Mil.): 219.12
Dividend: --
Yield (%): --

Financials

  BIIB.OQ Industry Sector
P/E (TTM): 18.13 37.66 37.54
EPS (TTM): 17.13 -- --
ROI: 23.33 14.54 13.98
ROE: 31.85 15.32 14.88

BRIEF-Anavex signs material transfer agreement with Biogen

* Signed material transfer agreement with Biogen under which Biogen will test Anavex's lead drug candidate, Anavex 2-73 Source text for Eikon: Further company coverage:

Sep 28 2016

BRIEF-Biogen completes submission of new drug application

* Biogen completes rolling submission of new drug application to FDA for nusinersen as a treatment for spinal muscular atrophy

Sep 26 2016

REFILE-DEALTALK-Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Sept 20 Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Sep 20 2016

Allergan pays top dollar for 'stepping stones' from neurology to dermatology

Allergan Plc CEO Brent Saunders calls them "stepping stones" - small, bolt-on acquisitions, as opposed to the mega-deals common in the drug industry. And they're expected to boost dealmaking in sectors ranging from neurology to skin care.

Sep 20 2016

BRIEF-Biogen Inc affirms strong efficacy of TECFIDERA in both clinical studies and real-world setting

* New Data Affirm Strong Efficacy And well characterized safety profile of TECFIDERA in both clinical studies and real-world setting

Sep 14 2016

BRIEF-BioMotiv and Biogen expand strategic partnership

* BioMotiv and Biogen expand strategic partnership into ophthalmology Source text for Eikon: Further company coverage:

Sep 06 2016

BRIEF-Biogen announces Bioverativ as name of new hemophilia-focused company

* Biogen announces Bioverativ as name of new hemophilia-focused company

Aug 09 2016

Biogen not pursuing a sale: source

U.S. biotechnology company Biogen Inc has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter. | Video

Aug 04 2016

Biogen not pursuing a sale - source

Aug 3 U.S. biotechnology company Biogen Inc has not received any formal expressions of interest from potential acquirers and is not actively soliciting takeover offers, according to a person familiar with the matter.

Aug 03 2016

BRIEF-Allergan has no interest in a Biogen deal - CNBC, citing sources

* Allergan has no interest in a Biogen deal - CNBC, citing sources

Aug 03 2016

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $117.45 -1.94
Pfizer Inc. (PFE.N) $33.56 -0.43
Novartis AG (NOVN.S) CHF77.25 -1.30
Merck & Co., Inc. (MRK.N) $61.71 -1.59
Roche Holding Ltd. (ROG.S) CHF241.80 -2.80
Roche Holding Ltd. (RO.S) CHF242.90 -2.00
Bayer AG (BAYGn.DE) €88.30 -0.96
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €68.03 -0.29
GlaxoSmithKline plc (GSK.L) 1,647.50p -7.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Wright Reports
$75.00
Provider : ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.